Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 16,138 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Breast Cancer
Interventions: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: MarginProbe, Lumpectomy; Device · Procedure
Lead sponsor: Dune Medical Devices; Industry
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 18
States / cities: Costa Mesa, California • Los Angeles, California • Newport Beach, California + 8 more

Conditions: Stage IV Melanoma, Stage III Melanoma
Interventions: Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC), Autologous PBMCs in GM-CSF (MC); Biological
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 18
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 14 more

Conditions: Sarcoma, Kaposi, HIV Infections, Lymphoproliferative Disorders
Interventions: A-007; Drug
Lead sponsor: DEKK-TEC, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Pressure Ulcer
Interventions: Use of CMAP app for education (in-hospital), Use of CMAP app (in-home); Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Actinic Keratosis
Interventions: ingenol mebutate, Placebo; Drug · Other
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Smithtown, New York

Conditions: Lupus Nephritis
Interventions: BMS-986165, Placebo, Mycophenolate Mofetil; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 40
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 31 more

Conditions: Macular Pigmentation, Skin Pigment
Interventions: Carotenoid measurements; Other
Lead sponsor: University of Utah; Other
Eligibility: 7 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Breast Cancer
Interventions: rubitecan; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Dublin, California

Conditions: Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Interventions: 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan; Drug
Lead sponsor: Actuate Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more

Conditions: Malignant Melanoma
Interventions: CancerVax vaccine (CANVAXIN); Biological
Lead sponsor: CancerVax Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 51
States / cities: Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 43 more

Conditions: Breast Cancer
Interventions: surveys completed by subject; Other
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Actinic Keratosis
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cancer-related Problem/Condition, Quality of Life, Stress, Emotional
Interventions: My Guide; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions: Biopsy, Capivasertib, Ceralasertib, Durvalumab, Olaparib, Quality-of-Life Assessment, Selumetinib; Procedure · Drug · Biological + 1 more
Lead sponsor: Gordon Mills, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Osteoporosis, Juvenile Rheumatoid Arthritis, Dermatomyositis, Polyarthritis, Systemic Lupus Erythematosis, Vasculitis, Glucocorticoid-induced Osteoporosis
Interventions: denosumab; Drug
Lead sponsor: Indiana University; Other
Eligibility: 4 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Sanfilippo Syndrome, Mucopolysaccharidosis III
Interventions: Epidiolex, Placebo; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 4 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Torrance, California

Conditions: Mastocytosis
Interventions: Not listed
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: Not listed
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Fabry Disease
Interventions: This is a non-interventional study; Other
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Eagan, Minnesota

Conditions: Vascular Ehlers-Danlos Syndrome
Interventions: ACER-002 (celiprolol) 200 mg BID, Placebo BID; Drug
Lead sponsor: Acer Therapeutics Inc.; Industry
Eligibility: 15 Years to 64 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Culver City, California

Conditions: Anxiety; Generalized, Breast Diseases, Surgery
Interventions: Lavender oil, Placebo; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
Interventions: monoclonal antibody Me1-14 F(ab')2; Biological
Lead sponsor: Duke University; Other
Eligibility: 3 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2001
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Duarte, California • Grand Rapids, Michigan • Long Island City, New York + 7 more

Conditions: Lichen Planopilaris
Interventions: Deucravacitinib; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Scottsdale, Arizona • Jacksonville, Florida

Search by objective public record fields.

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

CMAP Refinement for Pressure Injury Prevention

Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Macular Pigment Measurements in Eye & Other Tissues

Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

9-ING-41 in Patients With Advanced Cancers

Vaccine Therapy for Patients With Stage IV Melanoma

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms

Biomarker Database Registry for Photodynamic Therapy

A Research Study for Latina Women Undergoing Breast Cancer Treatment

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders

Study of Cannabidiol in Sanfilippo Syndrome

Mast Cell Connect: A Registry for Patients With Mastocytosis

Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome

Randomized, Placebo-Controlled Study: Effects of Lavender Aromatherapy on Preoperative Anxiety in Breast Patients

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

A Study of Deucravacitinib to Treat LPP and FFA